Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 4
2002 1
2004 2
2005 5
2006 11
2007 11
2008 19
2009 9
2010 14
2011 16
2012 10
2013 9
2014 13
2015 15
2016 11
2017 11
2018 11
2019 9
2020 7
2021 15
2022 6
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

184 results
Results by year
Filters applied: . Clear all
Page 1
Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ. Lenz HJ. Oncologist. 2007 May;12(5):601-9. doi: 10.1634/theoncologist.12-5-601. Oncologist. 2007. PMID: 17522249 Free article. Review.
Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and symptom management. Rechallenge should be considered after complete resolution of all symptoms. Severe reactions may require treatment dis …
Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and sympt …
Cetuximab-associated infusion reactions: pathology and management.
Patel DD, Goldberg RM. Patel DD, et al. Oncology (Williston Park). 2006 Oct;20(11):1373-82; discussion 1382, 1392-4, 1397. Oncology (Williston Park). 2006. PMID: 17112000 Free article. Review.
Although cutaneous manifestations are the most common toxicities associated with cetuximab, they are rarely life-threatening. Cetuximab-related infusion reactions are less common, but they may become severe and cause fatal outcomes if not managed appro …
Although cutaneous manifestations are the most common toxicities associated with cetuximab, they are rarely life-threatening. Cetu …
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Vermorken JB, et al. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. N Engl J Med. 2008. PMID: 18784101 Free article. Clinical Trial.
Patients with stable disease who received chemotherapy plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects, whichever occurred first. ...Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions …
Patients with stable disease who received chemotherapy plus cetuximab continued to receive cetuximab until disease progression …
Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A, Disson-Dautriche A, Miremont-Salamé G, Fourrier-Reglat A, Sgro C; Réseau des Centres Régionaux de Pharmacovigilance Français. Grandvuillemin A, et al. J Oncol Pharm Pract. 2013 Jun;19(2):130-7. doi: 10.1177/1078155212457965. Epub 2012 Nov 15. J Oncol Pharm Pract. 2013. PMID: 23154574
OBJECTIVES: To compare characteristics of patients exhibiting cetuximab infusion reactions or another adverse drug reaction related to cetuximab and to identify factors associated with the severity of cetuximab infusion reaction …
OBJECTIVES: To compare characteristics of patients exhibiting cetuximab infusion reactions or another adverse drug r …
Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Hopps S, et al. J Oncol Pharm Pract. 2013 Sep;19(3):222-7. doi: 10.1177/1078155212462440. Epub 2012 Nov 7. J Oncol Pharm Pract. 2013. PMID: 23135806
Cetuximab is generally well tolerated; however, hypersensitivity infusion reactions have been reported. ...The overall incidence proportion of severe hypersensitivity infusion reactions was 12.4%. Male patients had an increased incidence of seve …
Cetuximab is generally well tolerated; however, hypersensitivity infusion reactions have been reported. ...The overall …
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Bonner JA, et al. N Engl J Med. 2006 Feb 9;354(6):567-78. doi: 10.1056/NEJMoa053422. N Engl J Med. 2006. PMID: 16467544 Free article. Clinical Trial.
RESULTS: The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 months among those given radiotherapy alone (hazard ratio for locoregional progression or death, 0.68; P=0.005). ...With the exception of a …
RESULTS: The median duration of locoregional control was 24.4 months among patients treated with cetuximab plus radiotherapy and 14.9 …
Management of infusion reactions associated with cetuximab treatment: A case report.
Ohshita N, Ichimaru Y, Gamoh S, Tsuji K, Kishimoto N, Tsutsumi YM, Momota Y. Ohshita N, et al. Mol Clin Oncol. 2017 Jun;6(6):853-855. doi: 10.3892/mco.2017.1242. Epub 2017 May 5. Mol Clin Oncol. 2017. PMID: 28588776 Free PMC article.
The severity of infusion reactions (IR) is categorized from grade 1 to 5; grades 3 and 4 are associated with life-threatening reactions (anaphylaxis), whereas grade 5 indicates death. ...The timely diagnosis and treatment with intravenous infusion of a …
The severity of infusion reactions (IR) is categorized from grade 1 to 5; grades 3 and 4 are associated with life-threatening …
Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
Dupont M, Carlier C, Gower-Rousseau C, Barbier-Lider P, Botsen D, Brasseur M, Burgevin A, Chourbagi C, D'Almeida R, Hautefeuille V, Hentzien M, Lambert A, Lamuraglia M, Lavau-Denes S, Lopez A, Parent D, Slimano F, Brugel M, Bouché O. Dupont M, et al. BMC Cancer. 2022 Nov 25;22(1):1219. doi: 10.1186/s12885-022-10192-4. BMC Cancer. 2022. PMID: 36434607 Free PMC article.
BACKGROUND: Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states of the USA. Tick's bites were suspected of generating cross-reactions between cetux …
BACKGROUND: Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions …
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH. Chung CH. Oncologist. 2008 Jun;13(6):725-32. doi: 10.1634/theoncologist.2008-0012. Oncologist. 2008. PMID: 18586928 Free article. Review.
Although generally better tolerated with less toxicity than conventional anticancer agents, monoclonal antibodies may cause infusion-related reactions like other infusional agents. The incidence of infusion reactions varies by agent, but severe events …
Although generally better tolerated with less toxicity than conventional anticancer agents, monoclonal antibodies may cause infusion- …
184 results